W. Yao

The preliminary safety and immunogenicity results of a randomized, double-blind, placebo-controlled Phase I trial for a recombinant two-component subunit SARS-CoV-2 vaccine ReCOV

F. Zhu, J. Yu, J. Chen, 2022, medRxiv.

Clinical characteristics and prognostic value of 1q21 gain detected by fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma

X. Fang, W. Yao, Xiao Xiao, 2021, memo - Magazine of European Medical Oncology.

Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study.

N. Shire, Haiyi Jiang, S. Senan, 2019, Clinical lung cancer.

LBA4 GEMSTONE-302: A phase III study of platinum-based chemotherapy (chemo) with placebo or CS1001, an anti-PDL1 antibody, for first-line (1L) advanced non-small cell lung cancer (NSCLC)

H. Shen, Yan Yu, Yan Sun, 2020, Annals of Oncology.

Randomised clinical trial: prucalopride, a colonic pro‐motility agent, reduces the duration of post‐operative ileus after elective gastrointestinal surgery

J. Li, Z. Guo, Tenghui Zhang, 2016, Alimentary pharmacology & therapeutics.

Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer.

D. Jäger, H. Wakelee, S. Ou, 2016 .

Application of comprehensive unit-based safety program model to improve chemotherapy-induced nausea and vomiting in patients with ovarian cancer: a retrospective study

Jie Yang, Ting Zhao, Xinxin Xie, 2023, Journal of Ovarian Research.